Oragenics Inc. (NYSE American: OGEN) has provided a shareholder update highlighting progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI). The company reported active patient enrollment and dosing underway across multiple sites in Australia, while advancing U.S. regulatory preparations targeting a Type C FDA meeting request in the second quarter and an Investigational New Drug (IND) submission by year-end 2026.
Beyond the clinical trial update, Oragenics disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device, signaling a strategic expansion into broader neurological care. The company also reported a March 31, 2026, cash balance of $6.1 million, which is expected to support ongoing operations and development activities.
The Phase IIa trial is evaluating ONP-002, a potential first-in-class treatment for concussion and mTBI, using Oragenics' proprietary intranasal delivery technology. This platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The company's focus on brain-targeted therapeutics addresses significant unmet medical needs in neurological care.
The progress in Australia is a key milestone, as the company works toward initiating U.S. Phase 2b trials. The planned Type C meeting with the FDA is a critical step to align on the regulatory pathway for ONP-002, which could expedite development and bring a novel treatment to patients suffering from concussion, a condition with no currently approved therapies.
For more information on the full press release, visit https://ibn.fm/tEk2C. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.
